Davis Polk advised the joint book-running managers on an SEC-registered offering by Abbott Laboratories of $2.85 billion aggregate principal amount of 2.350% notes due 2019, $2.85 billion aggregate principal amount of 2.900% notes due 2021, $1.5 billion aggregate principal amount of 3.400% notes due 2023, $3 billion aggregate principal amount of 3.750% notes due 2026, $1.65 billion aggregate principal amount of 4.750% notes due 2036 and $3.25 billion aggregate principal amount of 4.900% notes due 2046. The net proceeds from the offering will fund a portion of the consideration for the acquisition of St. Jude Medical by Abbott, and to pay related expenses.

Abbott is a global healthcare company that researches and manufactures a range of medical technologies. With a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals, Abbott serves people in more than 150 countries and employs approximately 74,000 people.

The Davis Polk capital markets team included partner Deanna L. Kirkpatrick, counsel Jeffrey S. Ramsay and associates Christopher M. Bezeg and Andrew J. Terjesen. Counsel Loyti Cheng and associate Yuko Masunaga provided environmental advice. Partner Rachel D. Kleinberg and associate Dao Fu provided tax advice. Associates Bonnie Chen and Tilak Koilvaram provided intellectual property and technology advice. Members of the Davis Polk team are based in the New York and Northern California offices.

Copy link to share post